Table 8 Serious clinical adverse experiences irrespective of relationship to study drug that occurred at an incidence rate of ≥0.2% in any group
From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
| Â | Sitagliptin 100 mg n (%) (N = 3415) | Non-Exposed n (%) (N = 2724) | Difference between Sitagliptin and Non-Exposed % (95% CI)* |
|---|---|---|---|
Coronary Artery Disease | 5 (0.1) | 7 (0.3) | -0.1 (-0.4, 0.1) |
Myocardial Infarction | 4 (0.1) | 5 (0.2) | -0.1(-0.3, 0.1) |
Non-cardiac Chest Pain | 4 (0.1) | 9 (0.3) | -0.2 (-0.5, 0.0) |
Cholelithiasis | 6 (0.2) | 2 (0.1) | 0.1 (-0.1, 0.3) |
Pneumonia | 4 (0.1) | 5 (0.2) | -0.1 (-0.3, 0.1) |